Compare GBLI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBLI | CCCC |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.7M | 404.7M |
| IPO Year | 2010 | 2020 |
| Metric | GBLI | CCCC |
|---|---|---|
| Price | $27.22 | $3.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 5.8K | ★ 2.9M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $450,098,000.00 | $35,947,000.00 |
| Revenue This Year | $14.23 | N/A |
| Revenue Next Year | $9.68 | N/A |
| P/E Ratio | $94.83 | ★ N/A |
| Revenue Growth | ★ 2.02 | 1.02 |
| 52 Week Low | $24.28 | $1.69 |
| 52 Week High | $30.52 | $5.17 |
| Indicator | GBLI | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.28 |
| Support Level | N/A | $3.42 |
| Resistance Level | N/A | $3.91 |
| Average True Range (ATR) | 0.00 | 0.23 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 33.05 |
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.